ACM
SNDX icon

ADAR1 Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

ADAR1 Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,000
Closed -$2.02M – 291
2024
Q3 		$2.02M Buy
+105,000
New +$2.17M 0.33% 49

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

ADAR1 Capital Management's SNDX Position: Q1 2026 in Review

ADAR1 Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 46% in Q1 2026, buying an estimated $120K and bringing the position to 17,500 shares worth $409K. The position accounts for 0.02% of the portfolio, ranked #217.

ADAR1 Capital Management first reported a position in SNDX in Q3 2024 and has held it in 4 quarters since. The position peaked at $6.74M in Q3 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • ADAR1 Capital Management held 17,500 shares of Syndax Pharmaceuticals worth $409K as of Q1 2026.
  • ADAR1 Capital Management bought 5,500 Syndax Pharmaceuticals shares in Q1 2026, an estimated $120K.
  • Syndax Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #217 holding.
  • ADAR1 Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Syndax Pharmaceuticals position peaked at $6.74M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.